Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: Assessment of adequate renal function and influence on outcome

Effect of concomitant variant histology on the prognosis of patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy

“…However, in this study, we observed no differences in pure UTUC and UTUC with CVH among patients who received adjuvant chemotherapy on multivariate analysis for CSS, DFS, and OS, which is consistent with previous studies reported by Hellenthal et al. [28] and Yafi et al [29]. Notably, in our study, we found that tumor size Z3 cm was an unfavorable prognostic factor for CSS, DFS, and OS on both univariate and multivariate analysis; this was also observed by Espiritu et al [11] and Yuan et al [30].…”

The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy

“…Previous literatures have shown the survival prediction for metastatic UC after chemotherapy, mainly focusing on UCB [18][19][20][21][22][23][24][25][26]. There were limited studies to separately investigate or compare the prognostic factors between metastatic UTUC and UCB after cisplatin-based chemotherapy.…”

A contemporary review of management and prognostic factors of upper tract urothelial carcinoma

“…No prospective trials investigating the benefit of adjuvant chemotherapy (AC) exists, owing to difficultly in accruing patients. Available evidence mostly stems from retrospective cohort studies and relatively small prospective series of patients treated at academic centers [50][51][52][53][54][55][56][57][58].…”